News 31.07.17

Genomic drug sensitivity biomarker for TTK inhibitors published in Molecular Cancer Therapeutics

In a new publication, NTRC scientists propose mutations in the cancer hot spot region of the β-catenin gene (CTNNB1) as prognostic drug sensitivity biomarkers for TTK inhibitors.

Read more
News 03.07.17

New at Pivot Park – Atro Medical

ATRO Medical is focusing their R&D activities on the meniscus prothesis Trammpolin™.

Read more
News 27.06.17

NTRC expands Oncolines™ cell line panel to 102 cell lines

NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines.

Read more
News 07.06.17

Successful first-in-human study exploiting a unique scalable Natural Killer-cell product

We report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.

Read more
News 06.06.17

PimBio vestigt zich op Pivot Park

Per 1 juni zijn de deuren van het kantoor van PimBio op Pivot Park geopend.

Read more
News 31.05.17

NTRC publishes target residence time-guided optimization of TTK inhibitors

This week, NTRC published results from its TTK (Mps1) drug discovery programme in the Journal of Molecular Biology.

Read more
News 31.05.17

Pluriomics BV partners with Pivot Park Screening Centre

Pluriomics partners with Pivot Park Screening Centre for Cardiovascular drug discovery services.

Read more
News 16.05.17

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

Synaffix announced that a key patent covering its HydraSpace™ spacer technology has been granted by the US Patent and Trademark Office.

Read more
News 03.04.17

Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration

Lead Pharma announced that it has achieved a second milestone under its research collaboration with Sanofi.

Read more